NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSSeptember 30, 2013December 31, 2012
(1)Current assets:Cash and cash equivalents$
25,437Short-term investments118,139251,757Accounts receivable4,5575,805Inventory15,07618,269Other current assets4,75913,363Total current assets207,942314,631Restricted cash25,00025,000Property and equipment, net65,08272,215Goodwill76,50176,501Other assets8,5109,443Total assets$
497,790LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current liabilities:Accounts payable$
2,863Accrued compensation13,9108,773Accrued expenses10,7718,008Accrued clinical trial expenses15,23917,500Deferred revenue, current portion21,30021,896Interest payable3,1677,083Other current liabilities12,80312,414Total current liabilities80,91378,537Senior secured notes125,000125,000Capital lease obligations, less current portion9,00711,607Liability related to sale of future royalties, less current portion
125,167128,266Deferred revenue, less current portion82,23396,551Deferred gain1,7482,404Other long-term liabilities9,2178,407Total liabilities433,285450,772Commitments and contingenciesStockholders' equity (deficit) :Preferred stock--Common stock1111Capital in excess of par value1,636,1621,617,744Accumulated other comprehensive loss(1,689)(357)Accumulated deficit(1,684,734)(1,570,380)Total stockholders' equity (deficit) (50,250)47,018Total liabilities and stockholders' equity (deficit)
497,790(1) The consolidated balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements.
NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per s
|SOURCE Nektar Therapeutics|
Copyright©2012 PR Newswire.
All rights reserved